ERBB2 and cancer: The enrichment of Amp-650 in molecular subtypes with poor prognosis, HER2-enriched and basal, and in poorly differentiated BRCA led us to hypothesize that miR-650 may be targeting TSG to promote cancer aggressiveness and progression.